Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.

导出 OA

翻译打印收藏纠错

作者： Lucienne,Costa-Frossard França ^[1] ; Virginia,Meca Lallana ^[2] ; Andrés,Labiano-Fontcuberta ^[3] ; Rosario,Blasco ^[4] ; Enric,Monreal ^[1] ; María Luisa,Martínez Ginés ^[5] ; Clara,Aguirre ^[6] ; Julia,Sabin Muñoz ^[7] ; Susana,Sainz de la Maza ^[2] ; Juan Pablo,Cuello ^[4] ; Carolina,Díaz-Pérez ^[1] ; Juan Luis,Chico García ^[5] ; Alberto,Lozano Ros ^[6] ; Fernando,Rodríguez Jorge ^[7] ; Susana,Martínez Martínez ^[2] ; José Manuel,García Domínguez ^[1]

作者单位： Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain. ^[1] Demyelinating Diseases Unit, Neurology Service, Hospital Universitario La Princesa, Madrid, Spain. ^[2] Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain. ^[3] Neuroimmunology Unit, Neurology Service, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. ^[4] IRYCIS (Ramón y Cajal Institute for Health Research), Madrid, Spain. ^[5] REEM (Spanish Network of Multiple Sclerosis), Universidad de Alcalá, Madrid, Spain. ^[6] Department of Neurology, Hospital Universitario Gregorio Marañón, Madrid, Spain. ^[7] Medical Department of Neurology and Neuroimmunology, Sanofi, Barcelona, Spain. ^[8] Department of Neurology, Hospital Universitario Gregorio Marañón, Madrid, Spain. jgarciadominguez@salud.madrid.org. ^[9]

主题词成年人(Adult);人类(Humans);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);回顾性研究(Retrospective Studies);多发性硬化(Multiple Sclerosis);复发(Recurrence)

DOI 10.1007/s40263-024-01066-3

PMID 38418770

发布时间 2024-04-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交